-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although with the introduction of PET adaptation programs, the treatment of Hodgkin's lymphoma has made considerable progress, but the problems faced in practical applications hinder the wider application of these methods
.
The ECHELON-1 study evaluated the first-line A+AVD (bentuximab+doxorubicin+vinblastine+dacarbazine) versus ABVD (doxorubicin+bleomycin+vinblastine+dacarbazine) regimen For the efficacy and safety of stage III or IV classic Hodgkin's lymphoma
Lymphoma
This article reports the latest analysis results of the ECHELON-1 study after 5 years of follow-up
.
.
The ECHELON-1 study is an international, open-label, randomized phase 3 trial carried out in 218 clinical centers in 21 countries, recruiting untreated patients with stage III or IV classic Hodgkin’s lymphoma who are over 18 years of age.
1:1 randomized to receive A+AVD or ABVD treatment for 6 courses
.
The primary endpoint is adjusted progression-free survival
From November 19, 2012 to January 13, 2016, a total of 1334 patients received A+AVD (n=664) or ABVD (n=670) at random
.
After a median follow-up of 60.
The 5-year progression-free survival rates of the A+AVD group and the ABVD group were 82.
5-year progression-free survival rate of patients in the A+AVD group and ABVD group
5-year progression-free survival rate of patients in the A+AVD group and ABVD groupAmong patients with negative PET2, the 5-year progression-free survival rates of the A+AVD group and the ABVD group were 84.
9% (95% CI 81.
7–87.
6) and 78.
9% (75.
2–82.
1; HR 0.
66 [95% CI 0.
50–0 ·88]; p=0.
0035)
.
The 5-year progression-free survival rates of PET2-positive patients in the A+AVD group and ABVD group were 60.
In PET2-negative patients, the 5-year progression-free survival rates of the A+AVD group and ABVD group were 84.
In summary, after 5 years of follow-up, regardless of the status of PET-2, compared with the ABVD regimen, the A+AVD regimen showed a strong and lasting improvement in the progression-free survival rate of stage III or IV classic Hodgkin’s lymphoma.
, And the security is consistent
.
Based on these findings, the A+AVD regimen should be preferred for patients with stage III or IV classic Hodgkin’s lymphoma who have not been treated before
Compared with the ABVD regimen, the A+AVD regimen has shown a strong and lasting improvement in the progression-free survival rate of stage III or IV classic Hodgkin’s lymphoma.
Original source:
David J Straus, et al.
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial in this message